Latona Life Sciences

Latona Life Sciences is a biotechnology company and a subsidiary of Cambrian BioPharma, focused on developing novel small molecule therapeutics that enhance selective autophagy, specifically mitophagy. The company's mission is to treat age-related diseases by restoring the cell's ability to identify and degrade damaged mitochondria, a process that declines with age. By targeting specific adapters like p62, Latona aims to maintain cellular homeostasis and prevent the accumulation of mitochondrial dysfunction associated with neurodegeneration and metabolic disorders. Operating within Cambrian's hub-and-spoke 'PipeCo' model, the company leverages centralized drug development expertise to advance its pipeline of longevity-focused medicines. Latona's lead programs are currently in the pre-clinical stage, targeting high-impact indications such as Parkinson's disease.